Market research
CCCC C4 Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 492M
- P/E ratio
- Not available
- Analyst target
- 13.3333
- Dividend yield
- Not available
- Beta
- 2.95
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US12529R1077
- Market cap
- 492M
- P/E ratio
- Not available
- Analyst target
- 13.3333
- Dividend yield
- Not available
- Beta
- 2.95
About
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CCCC discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 1324.6% more expensive than other stocks from the Other sector with a price to sales ratio of 13.2.
Based on the above factors, C4 Therapeutics, Inc gets an overall score of 0/5.